Fried MW, Shiffman ML, Reddy KR, et al.
: Combination of peginterferon alfa-2a plus ribavirin in patients with chronic hepatitis C virus infection
. N Engl J Med
Manns MP, McHutchison JG, Gordon SC, et al.
: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
Muir AJ, Bornstein JD, Killenberg PG: Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites
. N Engl J Med
Jeffers LJ, Cassidy W, Howell CD, et al.
: Peginterferon alfa- 2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1
Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al.
: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients
. N Engl J Med
NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002, 19:1–46.
Davis GL, Wong JB, McHutchison JG, et al.
: Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
Hinrichsen H, Benhamou Y, Wedemeyer H, et al.
: Shortterm antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients
:1347–1355. The first study to show proof of principle of the efficacy of protease inhibitors. Although the trials for BILN 2061 were suspended because of toxicity, it paved the way for the development of similar agents.PubMedCrossRef
Press Release. Hepatitis C Drug Development at Boehringer Ingelheim. http://us.boehringer-ingelheim.com/about/pressreleases/ 102803_hepatitis.html. Accessed May 26, 2006.
Reesink HW, Zeuzem S, van Vliet A, et al.: Initial results of a phase 1B, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor [abstract]. Paper presented at Digestive Disease Week, Chicago, IL, May 14-19, 2005. Abstract 527.
Malcolm BA, Liu R, Lahser F, et al.
: SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells
. Antimicrob Agents Chemother
Zeuzem S, Sarrazin C, Rouzier R, et al.: Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (@#@ Peg-IFN-α @#@) [abstract]. Paper presented at 56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). San Francisco, CA, November 11-15, 2005.
Zeuzem S, Sarrazin C, Wagner F, et al.: Combination therapy with the HCV protease inhibitor, SCH 503034, plus Peg-Intron in hepatitis C genotype-1 Peg-Intron non-responders: phase Ib results [abstract]. Paper presented at 56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). San Francisco, CA, November 11-15, 2005. Abstract 201.
Malcolm BA, Zeuzem S, Gupta S, et al.: Modeling of HCV dynamics during combination therapy with peginterferon alfa-2b and the NS3 protease inhibitor SCH 503034 [abstract]. Paper presented at 56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). San Francisco, CA, November 11-15, 2005. Abstract 1266.
Zhou XJ, Afdhal N, Godofsky E, et al.: Pharmacokinetics and pharmacodynamics of valopicitabine (NM283), a new nucleoside HCV polymerase inhibitor: results from a phase I/II dose-escalation trial in patients with HCV-1 infection [abstract]. Paper presented at the 40th Annual Meeting of the European Association for the Study of the Liver (EASL), Paris, France, April 13-17, 2005. J Hepatol 2005, 42:229.
Afdhal N, Rodriguez-Torres M, Lawitz E, et al.: Enhanced antiviral efficacy for valopicitabine (NM283) plus peginterferon in hepatitis C patients with HCV genotype-1 infection: results of a phase IIa multicenter trial [abstract]. Paper presented at the 40th Annual Meeting of the European Association for the Study of the Liver (EASL), Paris, France, April 13-17, 2005. J Hepatol 2005, 42:39-40.
McHutchison J, Bartenschlager R, Patel K, et al.
: The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice [review]
. J Hepatol
:411–421. An excellent and comprehensive review of the new developments in hepatitis C treatment.PubMedCrossRef
Gish RG, Nelson D, Aurora S, et al.: Virologic response and safety outcomes in therapy naïve patients treated for chronic hepatitis C with viramidine in combination with pegylated interferon alfa-2a [abstract]. Paper presented at the 40th Annual Meting of the European Association for the Study of the Liver (EASL), Paris, France, April 13-17, 2005. Abstract 91.
McHutchison JG, Shiffman ML, Cheung RC: A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C
. Antivir Ther
Okuse C, Rinaudo JA, Farrar K, et al.
: Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy
. Antiviral Res
McHutchison J, Bacon B, Gordon SC, et al.: Relationships of HCV RNA responses to CPG 10101, a TLR9 agonist: pharmacodynamics and patient characteristics. Hepatology 2005, 42:249A.
Horsmans Y, Berg T, Desager JP, et al.
: Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection